Imv (NASDAQ: IMV)
$0.00
Imv Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Imv Company Info
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Valuation
Earnings Transcripts
IMV Inc. (IMV) Q2 2021 Earnings Call Transcript
IMV earnings call for the period ending June 30, 2021.
Motley Fool Transcribing | Aug 11, 2021
IMV Inc. (IMV) Q1 2021 Earnings Call Transcript
IMV earnings call for the period ending March 31, 2021.
Motley Fool Transcribing | May 12, 2021
IMV Inc. (IMV) Q4 2020 Earnings Call Transcript
IMV earnings call for the period ending December 31, 2020.
Motley Fool Transcribing | Mar 17, 2021
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.